drugset / Trial / NCT00839293

Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules

NCT00839293

Phase 1 Completed 32 enrolled Abbott
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and compare the bioavailability of fenofibric acid from 2 different dosage strengths of ABT-335.

Timeline

Start
2009-02
Primary completion
2009-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-335 Small molecule 45 mg
Subject ABT-335 Small molecule 135 mg

Indications

No indication recorded.